MOTS-C Half-Life: Not Established in Humans
MOTS-C is a 16-amino-acid mitochondria-derived peptide encoded in the 12S rRNA of the mitochondrial genome. It activates AMPK, promotes insulin sensitivity, and produces exercise-mimetic metabolic effects.[1] No published human pharmacokinetic study exists as of May 2026; plasma clearance likely occurs within minutes to low hours based on animal data and peptide degradation kinetics.
| MOTS-C — Quick Reference | |
|---|---|
| Plasma Half-Life | Not established in humans |
| Estimated Clearance (Animal) | Minutes to low hours (inferred) |
| Biological Effect Duration | Hours to days (AMPK pathway activation) |
| Primary Mechanism | AMPK activation via folate-cycle disruption; mitokine signalling |
| Administration Route | Subcutaneous injection (research use) |
| Molecular Weight | 2,174 Da (16 amino acids) |
| Sequence | MRWQEMGYIFYPRKLR |
| FDA Status | Not approved — research compound |
| Data Quality | Animal Study + early human observational — no published human PK study (May 2026) |
| Primary Reference | Lee C et al. Cell Metab 2015, PMID 25738459 |
What Is MOTS-C?
MOTS-C (Mitochondria-Originated Signal Transcript — Cytoplasm) is a 16-amino-acid peptide encoded within the 12S rRNA gene of the mitochondrial genome.[1] It was first characterised in 2015 by Lee et al., who demonstrated that MOTS-C regulates glucose and lipid metabolism by disrupting the folate cycle and activating AMP-activated protein kinase (AMPK).[1]
Unlike nuclear-encoded peptides, MOTS-C is transcribed from mitochondrial DNA (mtDNA) and translocates to the nucleus under metabolic stress, where it directly regulates gene expression.[2] This unique dual-compartment action — originating in mitochondria, acting in the nucleus — distinguishes MOTS-C from all other known longevity peptides.
Endogenous MOTS-C circulates in human plasma and declines with age.[3] Plasma levels increase acutely in response to exercise, suggesting MOTS-C may mediate some of the metabolic benefits of physical activity.[4]
Pharmacokinetics: What the Evidence Actually Shows
Plasma Clearance (Animal Models)
In rodent models, MOTS-C is rapidly degraded by circulating serine proteases and other peptidases. Based on the peptide's structural features — 16 unmodified amino acids, no PEGylation, no cyclisation — plasma half-life is estimated in the range of minutes to 1–2 hours, consistent with other unprotected small peptides of similar size. No human measurement has confirmed this range.[1]
Biological Effect Duration vs Plasma Half-Life
The critical distinction for MOTS-C is that biological effects persist far beyond plasma clearance. MOTS-C activates AMPK and subsequently alters gene expression in the nucleus — a downstream cascade that can sustain metabolic effects for hours to days after the peptide itself has been cleared from plasma.[1][2] This is analogous to other signalling peptides where receptor activation initiates a prolonged intracellular programme.
Endogenous Levels and Age-Related Decline
Kim SJ et al. (2018) demonstrated that circulating MOTS-C levels decline with age in humans.[3] Centenarians — individuals who reach 100+ years — show higher MOTS-C plasma levels than age-matched controls, suggesting a potential role in longevity phenotypes. This association is observational and does not establish causality.
Estimated Clearance Timeline (Animal Basis — Not Human Data)
| Half-Lives Elapsed | Estimated Time (Inferred) | % Remaining (Inferred) | Note |
|---|---|---|---|
| 1 half-life | ~30–60 min (inferred) | ~50% | Rapid initial degradation by plasma proteases |
| 2 half-lives | ~1–2 hours (inferred) | ~25% | Most plasma MOTS-C cleared |
| 3 half-lives | ~2–4 hours (inferred) | ~12% | Trace plasma levels only |
| 5 half-lives | ~4–8 hours (inferred) | <5% | Near-complete plasma clearance (animal basis) |
| Biological effects | Hours–days | N/A | AMPK activation and gene expression changes persist beyond plasma clearance |
Mechanism of Action
Folate Cycle Disruption and AMPK Activation
Lee et al. demonstrated that MOTS-C exerts its primary metabolic effect by interfering with the folate cycle — specifically the one-carbon metabolism pathway — which leads to reduced AICAR (aminoimidazole carboxamide ribonucleotide) phosphorylation and subsequent AMPK activation.[1] AMPK is the master energy-sensing kinase; its activation mimics the metabolic state of caloric restriction and exercise.
Nuclear Translocation Under Stress
Under metabolic stress conditions, MOTS-C translocates from mitochondria to the nucleus, where it directly regulates adaptive nuclear gene expression programmes.[2] This nuclear signalling function is unique among mitochondria-derived peptides and distinguishes MOTS-C from humanin, which acts primarily via cell-surface receptors.
Exercise-Induced Endogenous Release
Reynolds JC et al. (2021) demonstrated that endurance exercise increases circulating MOTS-C in humans.[4] Exogenous MOTS-C administration in aged mice improved exercise capacity, suggesting a potential role in exercise-related metabolic adaptation. Whether exogenous administration reproduces the same downstream cascade as endogenous exercise-induced MOTS-C release is not established.
Insulin Sensitivity and Glucose Metabolism
MOTS-C improves insulin sensitivity in diet-induced obese mice and increases glucose uptake in skeletal muscle via AMPK-dependent mechanisms.[1] These effects have not been replicated in controlled human intervention studies.
Route of Administration
| Route | Bioavailability | T½ Data | Notes |
|---|---|---|---|
| Subcutaneous injection | Not published | No published data | Standard route in animal studies; assumed for human research use |
| Intravenous | 100% (by definition) | No published data | Used in some animal studies; no human IV PK data available |
| Oral | Not established | No published data | Expected to be degraded by GI tract peptidases; no oral formulation studied |
| Intranasal | Not established | No published data | Not studied for MOTS-C |
MOTS-C vs Other Longevity & Metabolic Compounds
| Compound | Mechanism | Half-Life | Data Quality | Human PK? |
|---|---|---|---|---|
| MOTS-C | AMPK activation, folate-cycle disruption, nuclear gene regulation | Not established | Animal Study + early human observational | No |
| Epitalon | Telomerase activation (TERT), epigenetic regulation | ~30 min (estimated) | Animal Study + limited human observational | No |
| NAD+ Injectable | NAD+ repletion; sirtuin/PARP substrate replenishment | ~1–5 min plasma IV | Human PK Study (limited) | Yes (limited) |
| Humanin | Anti-apoptotic, neuroprotective; receptor-mediated (GHR, FPRL2) | Not established | Animal Study + human observational | No |
| GHK-Cu | Copper-chelating tripeptide; tissue remodelling, gene expression | ~30 min (estimated) | Animal Study + limited human data | No |
Human Observational Data
While no interventional human PK study exists, several observational studies have measured endogenous MOTS-C levels in human populations:
Kim SJ et al. (2018) found that healthy Korean centenarians had significantly higher circulating MOTS-C levels compared to younger (<35 years) and older (65–85 years) control groups.[3] This cross-sectional finding suggests an association between high MOTS-C and exceptional longevity, though confounders cannot be excluded.
Reynolds JC et al. (2021) demonstrated in a human exercise study that acute aerobic exercise significantly increased circulating MOTS-C, with levels peaking post-exercise and declining during recovery.[4] This is important context: MOTS-C is not exclusively an exogenous research compound — it is an endogenous mitokine with measurable dynamics in human plasma.
Dosing Considerations (Research Context Only)
This section summarises dosing parameters from animal studies and the limited research literature. This is not medical advice, and MOTS-C is not approved for human therapeutic use.
Animal studies have used doses ranging from 0.5 mg/kg to 5 mg/kg subcutaneously.[1] Human research protocols (from small conference presentations and non-peer-reviewed sources) have reported doses of 5–10 mg per injection, though no published peer-reviewed human dose-ranging study exists.
Track MOTS-C in Halflife
Log your compound schedule and track clearance windows based on known pharmacokinetics.
Download Halflife for iOSFrequently Asked Questions
What is the half-life of MOTS-C?
The half-life of MOTS-C has not been established in any published human pharmacokinetic study. Based on animal data and general small-peptide degradation kinetics, plasma clearance is estimated in the range of minutes to 1–2 hours, but this has not been confirmed in humans. The Data Quality rating for this page is Animal Study + early human observational.
How long does MOTS-C stay in your system?
There is no published human clearance data. Animal studies and structural analogy with similar peptides suggest plasma clearance within minutes to a few hours. However, the downstream biological effects — AMPK activation, altered gene expression, improved insulin sensitivity — may persist for hours to days after the peptide has been cleared from plasma.
What does MOTS-C do?
MOTS-C activates AMPK via disruption of the folate cycle, promotes glucose uptake in skeletal muscle, improves insulin sensitivity, and produces exercise-mimetic metabolic effects in animal models.[1] Under metabolic stress, it translocates to the nucleus and directly regulates gene expression programmes involved in metabolic adaptation.[2] Endogenous MOTS-C levels increase with exercise in humans.[4]
Is MOTS-C FDA approved?
No. MOTS-C is not FDA approved for any therapeutic indication. It is a research compound available for investigational use only. No Phase 3 clinical trial has been completed as of May 2026.
What is the difference between MOTS-C and humanin?
Both are mitochondria-derived peptides (MDPs) encoded in the mitochondrial genome. MOTS-C (16 aa, 12S rRNA-encoded) primarily regulates metabolic function via AMPK and nuclear translocation. Humanin (21 aa, 16S rRNA-encoded) exerts anti-apoptotic and neuroprotective effects via cell-surface receptors (GHR, FPRL2). They have distinct sequences, receptors, and primary biological functions.
Does MOTS-C increase with exercise?
Yes. Reynolds JC et al. (2021) demonstrated that acute aerobic exercise significantly increases circulating MOTS-C levels in humans.[4] Levels peak post-exercise and decline during the recovery period. This suggests that endogenous MOTS-C release may mediate some metabolic adaptations to exercise, which is the basis for the "exercise mimetic" designation for exogenous MOTS-C supplementation.
Can MOTS-C be detected on a drug test?
No validated anti-doping detection methodology has been published for exogenous MOTS-C. WADA's prohibited list includes peptide hormones and related substances; exogenous MOTS-C administration would likely fall under this category for regulated sports. No detection window data exists as of May 2026.
How is MOTS-C different from other longevity peptides?
MOTS-C is the only known longevity peptide encoded by the mitochondrial genome (rather than nuclear DNA). Its primary mechanism — folate-cycle disruption leading to AMPK activation — and its ability to translocate to the nucleus are unique among characterised mitokines. Unlike Epitalon (telomerase activator) or NAD+ (metabolic cofactor replenishment), MOTS-C acts as a retrograde signal from mitochondria to the nucleus to coordinate cellular metabolic state.
References
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID 25738459
- Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524. PMID 30017357
- Kim SJ, Mehta HH, Wan J, Kuehnemann C, Chen J, Hu JF, Hoffman AR, Cohen P. Mitochondrial peptides are associated with longevity and decrease in the elderly. Aging (Albany NY). 2019;11(6):1975-1986. PMID 30911685
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mann CJ, Kim YC, Victoria B, Liu C, Bass M, Bhaga S, Kim SJ, Rankin L, Cohen P, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID 33469016
- Cobb LJ, Lee C, Xiao J, Yen K, Wong RG, Nakamura HK, Mehta HH, Gao Q, Ashur C, Huffman DM, Wan J, Muzumdar R, Barzilai N, Cohen P. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging (Albany NY). 2016;8(4):796-809. PMID 27070252
Related Compounds
Log MOTS-C in Halflife
Track your peptide schedule, clearance windows, and dosing history in one place.
Download Halflife for iOS →